Information Hub

Clinical News

2018-06-30

Is Immunotherapy Right for Me?

Cancer immunotherapy has been hailed as the most promising treatment against cancer in recent decades, but what exactly is immunotherapy? Is Immunotherapy right for me?

Source:

2018-06-04

Circulating tumor DNA is a tool for disease monitoring in patients with pancreatic cancer

There are different treatments for metastatic pancreatic cancer patients. Therefore, disease monitoring is important for selecting effective treatments. This study indicated that circulating tumor DNA is an effective tool for disease monitoring in patient

Source:

Perets R, et al, Oncologist. 23(5):566-572, 2018

2018-06-04

Potential druggable mutations can be identified by circulating tumor DNA in advanced hepatocellular carcinoma

In this study, next generation sequencing (68 genes) was used to detect ctDNA in 14 patients with advanced HCC. The data indicated that ctDNA is an alternative tool for getting genetic information, and have the potential for targeted treatment selection i

Source:

Ikeda S, et al, Oncologist, 23(5):586-593, 2018

2018-06-04

Frontline pembrolizumab combination improves survival in metastatic lung cancer

Combining pembrolizumab with chemotherapy in the frontline setting significantly prolonged overall and progression-free survival in previously untreated metastatic non-squamous lung cancer without EGFR or ALK mutations, according to an international phase

Source:

Gandhi, L. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1801005 (2018)

2018-06-04

Mutation burden as a predictive biomarker in first-line immunotherapy for NSCLC

A study showed that in NSCLC patients with high mutation burden, nivolumab plus ipilimumab significantly improved progression-free survival than chemotherapy.

Source:

Hellmann, M. D. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1801946 (2018)

2018-06-04

New genes found related to hereditary diffuse gastric cancer

It is difficult to do a risk assessment or risk-reducing surgery in patients with hereditary diffuse gastric cancer whothat do not carry a CDH1 pathogenic variant, due to limited data availability. This study aimed to identify new genes associated with th

Source:

https://www.thelancet.com/journals/langas/article/PIIS2468-1253(18)30079-7/fulltext

2018-05-02

The Cancer Genome Atlas published the latest study results of the pan-cancer molecular features

The Cancer Genome Atlas (TCGA) analyzed the molecular information and the clinical data from more than 10,000 tumors across 33 types of cancers. These findings described the new molecular characteristics of subtypes in pan-cancer, which could serve as a b

Source:

The Cancer Genome Atlas. Cell. 173(2):321-337.e10 (2018)

2018-05-02

The new combination therapy showed clinical benefit for BRAF-mutant melanoma

In a randomized phase III trial (COLUMBUS), patients with BRAFV600E or BRAFV600K advanced, unresectable or metastatic melanoma were treated with the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib to identify its clinical activity. The result

Source:

Dummer R, et al. Lancet Oncol. pii: S1470-2045(18)30142-6 (2018)

2018-05-02

Osimertinib poised to be first-line standard of care in advanced EGFR mutation-positive NSCLC

In a phase III trial (FLAURA), advanced NSCLC patients with EGFR mutations (exon 19 deletion or L858R mutation) were treated with osimertinib. The results suggested that osimertinib could be a suitable first-line treatment for advanced EGFR mutation-posit

Source:

Soria JC, et al. N. Engl. J. Med. 378, 113–125 (2018)

2018-05-02

FDA accepted the regulatory submissions for review of a new second-generation EGFR inhibitor in first-line NSCLC

The FDA accepted the regulatory submissions for review of dacomitinib for first-line treatment of patients with NSCLC. The submissions are based on a randomized phase III trial (ARCHER 1050). In this trial, patients with EGFR-mutated (exon 19 deletion or

Source:

Wu YL, et al. Lancet Oncol. 18(11):1454-1466 (2017)